Alison - US: CFS/ME (LDN; low dose naltrexone)

Long COVID: major findings, mechanisms and recommendations

Nature reviews: microbiology
13 January 2023
https://www.nature.com/articles/s41579-022-00846-2

Researchers launch trial to treat long COVID with drug used to block effects of opioids

ABC Gold Coast
20 December 2022
https://www.abc.net.au/news/2022-12-21/long-covid-treatment-trial-drug-low-dose-naltrexone/101770626?utm_source=abc_news_web&utm_medium=content_shared&utm_campaign=abc_news_web

Addiction drug shows promise lifting long COVID brain fog, fatigue

Reuters
18 October 2022
https://www.reuters.com/business/healthcare-pharmaceuticals/addiction-drug-shows-promise-lifting-long-covid-brain-fog-fatigue-2022-10-18/

Queensland could open long COVID clinics as doctors seek to understand the condition

ABC News online
10 July 2022
https://www.abc.net.au/news/2022-07-11/queensland-coronavirus-long-covid-clinics/101221930

Queensland Health is investigating the possibility of establishing long COVID clinics as the third wave of Omicron intensifies. South Australia, Victoria, NSW and the ACT have already set up long COVID clinics. 

LDN in Clinical Practice - Andrew McCall, MB, ChB, DFM (2021 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - Causes of Hashimoto's (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD discusses Hasimoto’s thyroiditis at the LDN 2019 Conference. He discusses the mechanisms of thyroid dysfunction, causes and evaluation of Hashimoto’s thyroiditis, Hashimoto’s in obesity, and treatments of Hasimoto's